Back to top

Image: Bigstock

Tandem Releases Positive Results Of t:slim X2 Pump Studies

Read MoreHide Full Article

Tandem Diabetes Care, Inc. (TNDM - Free Report) , recently announced positive results from two studies of the t: slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology. Details from the two studies, which included Protocol 3 (DCLP3) of the National Institutes of Health (NIH)-funded International Diabetes Closed Loop (iDCL) trial and provisional data from the Freelife Kid AP study, were presented recently at the 79th Scientific Sessions of the American Diabetes Association (ADA).

The results of the studies are considered to be a major breakthrough by the company in the field of diabetes management.

Results in Details

The t:slim X2 insulin pump with Control-IQ technology uses Dexcom G6 CGM sensor values to forecast glucose levels and adjust insulin delivery to ensure the prevention of erratic highs and lows.

The NIH-funded DCLP3 study was performed on people with and without prior experience with insulin pump therapy. Those using Control-IQ technology also saw statistically significant improvements in HbA1c and reductions in mean glucose. A case of diabetic ketoacidosis (DKA) was reported in the Control-IQ study arm due to an infusion set failure.  Moreover, no severe hypoglycemia was reported in the study.

The Freelife Kid AP study is a multi-center, randomized evaluation of the proficiency of closed-loop insulin therapy in prepubertal children. The study participants using Control-IQ technology showcased a reduction in mean glucose.  Moreover, no case of severe hypoglycemia was reported in this case as well.

The results prove that t:slim X2 insulin pump with Control-IQ technology helps to  improve glycemic control and is convenient for patients to use.

Market prospects

Per Transparency Market Research, the global insulin pumps market is projected to reach around $9.50 billion by the end of 2025. The market is anticipated to witness a CAGR of 9.80% during 2017-2025. Hence, the outcomes of these studies are well-timed.

Recent Developments

Lately, Tandem Diabetes is investing in several developments pertaining to the t:slim X2 insulin pump.

In March 2019, the company announced that it is now registered as an approved vendor of insulin pumps and supplies under the Assistive Devices Program (ADP) in Ontario, Canada. In October 2018, the company received a Heath Canada Medical Device License for the t:slim X2 Insulin Pump.  Equipped with a Dexcom G5 Mobile continuous glucose monitoring (CGM) integration, it is the only CGM-integrated insulin pump approved in Canada for making daily diabetes treatment decisions without fingersticks. Recently, the company also announced that FDA has classified the t:slim X2 insulin pump as the first in a new device category — Alternate Controller Enabled Infusion Pumps (ACE pumps).

Price Performance

In the past one year, the company’s shares have outperformed the industry. The stock has improved 339.1% compared with the industry’s 3% decline.

Zacks Rank and Key Picks

Tandem Diabetes currently carries a Zacks Rank #3 (Hold).

Some other better-ranked stocks in the broader medical space are Cerner Corporation (CERN - Free Report) , Penumbra (PEN - Free Report) and Bruker Corporation (BRKR - Free Report) . While Cerner sports a Zacks Rank #1 (Strong Buy), Penumbra and Bruker carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Cerner’s long-term earnings growth rate is expected to be 13.5%.

Penumbra’s long-term earnings growth rate is projected at 21.5%.

Bruker’s long-term earnings growth rate is estimated at 11.7%.

Breakout Biotech Stocks with Triple-Digit Profit Potential

 The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>